Supplementary Figures 1 through 12 from Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non–Small Cell Lung Cancer
Supplementary Figure S1. The designed amino acid sequence of SIRPalphaD1-Fc. Supplementary Figure S2. Macrophage-mediated cytotoxicity in NSCLC cells after treatment with SIRPalphaD1-Fc. Supplementary Figure S3. SIRPalphaD1-Fc induced accumulation of autophagosomes and triggered autophagic flux in NSCLC cells. Supplementary Figure S4. Inhibiting autophagy enhanced macrophage-mediated phagocytosis. Supplementary Figure S5. Rapamycin exhibited negligible effect on the cytotoxicity mediated by macrophage against NSCLC cells. Supplementary Figure S6. Inactivation of Akt/mTOR signaling pathway after NSCLC cells treated with SIRPalphaD1-Fc. Supplementary Figure S7. Inactivation of Akt/mTOR signaling pathway in vivo after SIRPalphaD1-Fc treatment. Supplementary Figure S8. Representative fluorescence images of A549 cells co-stained with Cyto-ID(c) green dye and MitoSox(tm) red dye after exposed to SIRPalphaD1-Fc for the indicated time. Supplementary Figure S9. Photos of NSCLC xenograft tumors after treatment with SIRPalphaD1-Fc and/or chloroquine. Supplementary Figure S10. Analysis of SIRPalphaD1-Fc-treated A549 xenograft tumor tissues by TEM, H&E and immunohistochemistry staining. Supplementary Figure S11. Representative fluorescence images of ROS formation in NCI-H1975 xenograft tumors. Supplementary Figure S12. Simultaneously targeting CD47 and autophagy activated apoptosis-related pathways in vivo.